Lecture image placeholder

Premium content

Access to this content requires a subscription. You must be a premium user to view this content.

Monthly subscription - $9.99Pay per view - $4.99Access through your institutionLogin with Underline account
Need help?
Contact us
Lecture placeholder background
VIDEO DOI: https://doi.org/10.48448/smdc-kx33

technical paper

ENDO 2022

July 11, 2022

Atlanta, United States

Achievement of HbA1c <6.5% without weight gain and hypoglycemia in people with type 2 diabetes treated with tirzepatide across the phase 3 SURPASS program

Please log in to leave a comment

Downloads

Transcript English (automatic)

Next from ENDO 2022

Phase 1, Randomized, Controlled Trial of GFB-024, a Once-Monthly CB1 Inverse Agonist, in Healthy Overweight and Obese Participants and in Participants with Type 2 Diabetes Mellitus
technical paper

Phase 1, Randomized, Controlled Trial of GFB-024, a Once-Monthly CB1 Inverse Agonist, in Healthy Overweight and Obese Participants and in Participants with Type 2 Diabetes Mellitus

ENDO 2022

Sanela Bilic

11 July 2022

Similar lecture

Paracrine Growth Factor Signaling Regulates Muscle Regeneration in Aged Mice via microRNA 501
technical paper

Paracrine Growth Factor Signaling Regulates Muscle Regeneration in Aged Mice via microRNA 501

ENDO 2022

Alexandra Fahrner

11 July 2022

Stay up to date with the latest Underline news!

Select topic of interest (you can select more than one)

PRESENTATIONS

  • All Lectures
  • For Librarians
  • Resource Center
  • Free Trial
Underline Science, Inc.
1216 Broadway, 2nd Floor, New York, NY 10001, USA

© 2023 Underline - All rights reserved